Comment

  • 15 June 2018

    Lanabecestat termination: another blow for BACE inhibitors

    After the disappointing failures of highly anticipated anti-amyloid pipeline drugs, such as Pfizer/Johnson & Johnson’s bapineuzumab and Eli Lilly’s solanezumab, the focus of research in Alzheimer’s has increasingly turned to...

  • 12 June 2018

    Unmet needs must be addressed to optimise AIS management

    While the last two decades have brought important advances in our knowledge of stroke pathophysiology, awareness of symptoms, and improvements in acute stroke care, significant clinical and environmental unmet needs...